Safe­ty con­cerns cause GSK to stop high­ly an­tic­i­pat­ed vac­cine tri­al in sur­prise set­back

Days af­ter putting a trio of vac­cine tri­als on vol­un­tary pause, Glax­o­SmithK­line is of­fi­cial­ly stop­ping en­roll­ment and vac­ci­na­tion in tri­als in­volv­ing its res­pi­ra­to­ry syn­cy­tial virus (RSV) ma­ter­nal vac­cine can­di­date in preg­nant women.

In a state­ment to End­points News, a GSK spokesper­son con­firmed that the de­ci­sion is based on the same “ob­ser­va­tion from a rou­tine safe­ty as­sess­ment” that had led to the pause.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER